Last update 19 Jun 2024
Aflibercept/Nesvacumab
Last update 19 Jun 2024
Overview
Basic Info
Drug Type Fusion protein |
Synonyms Aflibercept/Ang2-antibody, Ang2 antibody/Eylea, Ang2-antibody/aflibercept + [6] |
Target |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Gene Sequence
Sequence Code 4715606
The sequence is quoted from: *****
Sequence Code 10152848H
The sequence is quoted from: *****
Sequence Code 10152862L
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Aflibercept/NesvacumabA Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
100 Clinical Results associated with Aflibercept/Nesvacumab
Login to view more data
100 Translational Medicine associated with Aflibercept/Nesvacumab
Login to view more data
100 Patents (Medical) associated with Aflibercept/Nesvacumab
Login to view more data
100 Deals associated with Aflibercept/Nesvacumab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetic macular oedema | Phase 2 | US | 02 Mar 2016 | |
| Dystrophy, Macular | Phase 2 | - | - | |
| Wet Macular Degeneration | Phase 2 | US | - | |
| Choroidal Neovascularization | Phase 1 | US | 01 Nov 2014 | |
| Wet age-related macular degeneration | Phase 1 | US | 01 Nov 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 302 | (REGN910-3 (3 mg: 2 mg)) | kkqryjeqwl(hqcdmdmyxa) = uipiayiynd wjldfsxkil (uwzfvsrogh, wwnkbybkar - icdxkctelq) View more | - | 03 Oct 2018 | ||
(REGN910-3 (6 mg:2 mg)) | kkqryjeqwl(hqcdmdmyxa) = jivmxavydd wjldfsxkil (uwzfvsrogh, kbfmkdpxnf - dngaqmgwbd) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free